Comparative Pharmacology
Head-to-head clinical analysis: BRISTACYCLINE versus DORYX MPC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTACYCLINE versus DORYX MPC.
BRISTACYCLINE vs DORYX MPC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTACYCLINE is a tetracycline antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
250 mg orally every 6 hours for 7-14 days.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
None Documented
None Documented
6-12 hours (terminal). In renal impairment, half-life extends up to 24-48 hours; dose adjustment required for CrCl <30 mL/min.
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Renal (40-60% unchanged), fecal (20-30%, primarily as inactive metabolites). Biliary excretion contributes minimally (<5%).
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic